Search Medical Condition
Please enter condition
Please choose location

Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

RESULTS

Found (123) clinical trials

Apheresis and Specimen Collection Procedures to Obtain Plasma Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

Protocol Design: This protocol is designed to perform collection of human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or body fluids to support research studies. These samples will be used by laboratory researches in their work on the development of vaccines for HIV and other infectious diseases, ...

Phase N/A

0.0 miles

Learn More »

The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or metastatic HER2-negative breast cancer who are resistant to or have failed prior taxane and an anthracycline ...

Phase

1.23 miles

Learn More »

This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop ...

Phase

1.23 miles

Learn More »

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ...

Phase

1.23 miles

Learn More »

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

Phase

1.67 miles

Learn More »

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected ...

Phase

1.81 miles

Learn More »

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.

Phase

1.81 miles

Learn More »

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Phase

1.81 miles

Learn More »

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer

The purpose of this study is to determine whether Nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Phase

1.81 miles

Learn More »

Safety Tolerability Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Phase

1.81 miles

Learn More »